Medtronic's MiniMed Split-Off Roadshow Details Exchange Terms and Pipeline Momentum
MMED sits 97% above its 52-week low of $10.65.
Summary
Medtronic's split-off roadshow quantifies the exchange offer terms and showcases MiniMed's accelerating growth and pipeline execution ahead of the October 9 expiration.
Key Events · M&A and Partnerships · MMED
-
Exchange Offer Terms Quantified
Target discount of 7% on MiniMed shares based on VWAP average during October 5-7 pricing period; maximum exchange ratio of 4.5939 MiniMed shares per Medtronic share; minimum 49.1M Medtronic shares (3.8% outstanding) to be repurchased; offer expires October 9.
-
Q1 FY27 Financial Performance
Revenue of $843 million grew 16.6% reported and 15.8% organic; adjusted EBITDA of $83.1 million at 9.9% margin, up 500 bps year-over-year; CGM attachment rate reached 69%.
-
Pipeline Ahead of Schedule
MiniMed Fit™ patch pump submitted to FDA ahead of Fall target; MiniMed Flex™ received CE Mark ahead of calendar year-end target; Vivera™ fully closed loop pivotal trial fully enrolled; next-gen extended wear sensor IDE approved.
-
Blackstone Funding Details
$324 million total Blackstone funding recognized as of April 2025; FDA approval of MiniMed Flex™ triggered a $157 million one-time accrual charge; royalty structure includes mid-to-high single digit percentage of net sales.
Analysis · MMED · Industrial Applications And Services
This roadshow presentation provides the most detailed look yet at Medtronic's planned divestiture of its MiniMed stake. The exchange offer mechanics are now fully quantified: a 7% target discount on MiniMed shares, a maximum exchange ratio of 4.5939 MiniMed shares per Medtronic share, and a minimum repurchase of 49.1 million Medtronic shares (3.8% of outstanding). The presentation also reveals strong operational momentum — Q1 FY27 revenue of $843 million grew 16.6% reported, with adjusted EBITDA margin expanding to 9.9% — and a pipeline that is ahead of schedule on multiple fronts. For Medtronic shareholders, this is the key document for evaluating whether to tender shares in the exchange offer.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.6% of the 1609 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MMED was trading at $21.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.9B. The 52-week trading range was $10.65 to $24.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.